)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Artelo Biosciences
Artelo Biosciences (ARTL) investor relations material
Artelo Biosciences H.C. Wainwright 28th Annual Global Investment Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.H.C. Wainwright 28th Annual Global Investment Conference summary11 Sep, 2026
Corporate overview and strategy
Focused on lipid signaling modulation with three main drug candidates targeting large, unmet medical needs in cancer anorexia, glaucoma, pain, and anxiety disorders.
Two assets are in-licensed (from AstraZeneca and Stony Brook University), and one is proprietary.
Robust patent estate with issued composition of matter patents in 22 countries for the co-crystal asset.
Leadership team highlighted for deep industry experience and successful track record.
Capitalization includes just under 5 million shares outstanding, over $4 million in cash, and no debt.
ART27.13 (Cancer Anorexia and Glaucoma)
ART27.13 is a synthetic dual cannabinoid receptor agonist, peripherally selective, avoiding CNS side effects.
Phase I showed two-thirds of patients stabilized or gained weight; phase II interim data showed 6% average weight gain at top dose, with improved physical activity and quality of life.
No serious adverse events in phase I or II; well-tolerated up to 1,300 mcg.
Glaucoma pilot phase II (DREAM trial) fully funded externally, results expected by year-end or early next year.
Lower dose used in glaucoma trial to minimize risk of weight gain in elderly population.
ART26.12 (FABP5 Inhibitor for Pain and Inflammation)
Targets fatty acid binding protein 5, with potential in pain, inflammation, and chemotherapy-induced peripheral neuropathy.
Preclinical models showed positive results in pain reduction.
Phase I completed with excellent safety profile; no drug-attributed toxicities in 55 subjects.
Linear pharmacokinetics and wide therapeutic window demonstrated.
Can be dosed in fed or fasted state, offering flexibility.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Artelo Biosciences
- Lead drug candidates show clinical promise in major markets, backed by robust patents and expertise.ARTL
Corporate presentation - Net loss narrowed, cash improved with $11M financing, but future depends on new funding.ARTLQ2 2026
- All proposals, including director elections and share increases, were approved.ARTLAGM 2026
- Shareholders urged to vote before July 17, 2026, to ensure quorum and efficient meeting conduct.ARTLProxy filing
- Shareholders can vote on key proposals at the July 17, 2026, annual meeting.ARTLProxy filing
- Shareholders will vote on director elections, share authorization, and a major equity issuance.ARTLProxy filing
- Multiple clinical milestones expected in the next 18 months across a diverse therapeutic pipeline.ARTLH.C. Wainwright 26th Annual Global Investment Conference 2024
- Shareholders will vote on director elections, a large share increase, and a major equity issuance.ARTLProxy filing
- Lead drug candidates advance in cancer, pain, and anxiety with strong safety and efficacy data.ARTLCorporate presentation
Next Artelo Biosciences earnings date
Q3 202612 Nov, 2026
Artelo Biosciences
Next Artelo Biosciences earnings date
Q3 202612 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Artelo Biosciences Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of proprietary therapeutics. These therapeutics are designed to modulate lipid-signaling pathways, including the endocannabinoid system, aiming to address significant unmet medical needs across various diseases and conditions such as anorexia, cancer, anxiety, pain, neuropathy, and inflammation. Artelo is advancing a diverse portfolio of product candidates, including ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist for treating anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal targeting inflammatory bowel disease and post-traumatic stress disorder (PTSD); and ART26.12, a fatty acid binding protein 5 inhibitor intended for breast and prostate cancer, neuropathic and nociceptive pain, and anxiety disorders, including PTSD. The company is headquartered in Solana Beach, California, and its shares are listed on the Nasdaq.